Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture
Neostigmine and Glycopyrrolate for the Treatment of Post Dural Puncture Headache After Known Dural Puncture With a Tuohy Needle: A Pilot Study
Mayo Clinic
18 participants
Nov 19, 2021
INTERVENTIONAL
Summary
The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.
Eligibility
Inclusion Criteria2
- Post-dural puncture headache (PDPH) after documented dural puncture with Tuohy needle during placement of epidural analgesia for labor and no other explanation for headache (HA).
- Onset of HA within 72 hours of delivery.
Exclusion Criteria12
- Patient refusal.
- Visual analog scale (NRS) score < 4.
- History of migraine headaches.
- Asthma.
- Arrhythmia.
- Heart block.
- Myasthenia gravis.
- Inability to understand pain scores and other questionnaires.
- Inability to speak English.
- Contraindication to acetaminophen or NSAIDs.
- Temperature > 38.5 C.
- Prior EBP done for this HA.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
IV infusion 20 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses
IV infusion 4 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05116930